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ABSTRACT: The purpose of this study was to compare the expression profiles of drug-
metabolizing enzymes in the intestine of mouse, rat and human. Total RNA was isolated from the
duodenum and the mRNA expression was measured using Affymetrix GeneChip oligonucleotide
arrays. Detected genes from the intestine of mouse, rat and human were ca. 60% of 22690 sequences,
40% of 8739 and 47% of 12559, respectively. Total genes of metabolizing enzymes subjected in this
study were 95, 33 and 68 genes in mouse, rat and human, respectively. Of phase I enzymes, the
mouse exhibited abundant gene expressions for Cyp3a25, Cyp4v3, Cyp2d26, followed by Cyp2b20,
Cyp2c65 and Cyp4f14, whereas, the rat showed higher expression profiles of Cyp3a9, Cyp2b19,
Cyp4f1, Cyp17a1, Cyp2d18, Cyp27a1 and Cyp4f6. However, the highly expressed P450 enzymes
were CYP3A4, CYP3A5, CYP4F3, CYP2C18, CYP2C9, CYP2D6, CYP3A7, CYP11B1 and CYP2B6 in
the human. For phase II enzymes, glucuronosyltransferase Ugt1a6, glutathione S-transferases
Gstp1, Gstm3 and Gsta2, sulfotransferase Sult1b1 and acyltransferase Dgat1 were highly expressed
in the mouse. The rat revealed predominant expression of glucuronosyltransferases Ugt1a1 and
Ugt1a7, sulfotransferase Sult1b1, acetyltransferase Dlat and acyltransferase Dgat1. On the other
hand, in human, glucuronosyltransferases UGT2B15 and UGT2B17, glutathione S-transferases
MGST3, GSTP1, GSTA2 and GSTM4, sulfotransferases ST1A3 and SULT1A2, acetyltransferases
SAT1 and CRAT, and acyltransferase AGPAT2 were dominantly detected. Therefore, current data
indicated substantial interspecies differences in the pattern of intestinal gene expression both for
P450 enzymes and phase II drug-metabolizing enzymes. This genomic database is expected to
improve our understanding of interspecies variations in estimating intestinal prehepatic clearance
of oral drugs. Copyright r 2009 John Wiley & Sons, Ltd.
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Introduction
Recent advances in genomic technology have
facilitated the rapid and simultaneous determina-
tion of global profiles for thousands of genes
in tissue samples directly associated with the
pharmacokinetics [1–5]. The completion of the
DNA sequencing of human, mouse and rat
genomes and knowledge of cross-species gene
homologies enables studies of differential gene
expression in animal models [6]. Recent targeting
of specific tissue genes, such as intestinal trans-
porters or enzymes, has shown a potential to
greatly enhance our understanding of pharmaco-
kinetics including bioavailability and metabolic
clearance for oral drug molecules [7–12]. It is now
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accepted that the drug absorption process from
the intestine is highly associated with the func-
tional gene expression of intestinal transporters
and metabolizing enzymes [7,13].
Many drugs are chemically altered in the body
by various reactions of metabolizing enzymes.
The key human enzyme subfamilies include
CYP1A, CYP2A, CYP2B, CYP2C, CYP2E and
CYP3A. It has been also generally understood
that the major metabolizing enzymes are
CYP3A4, CYP2D6, CYP2C8/9 and CYP1A2 in
human. Each enzyme subfamily possesses spe-
cific selectivity toward substrate drugs. CYP3A4
shows mostly wide spectra for the metabolism of
numerous drugs [14,15]. CYP2D6 metabolizes
amoxapine, chloropromazine, and codeine, and
CYP2C8/9 metabolizes phenytoin, ketamine,
paclitaxel, rifampin and various sulfonamides.
Although the enzymes are predominantly found
in the liver, the intestinal enzymes also deserve a
special mechanism for modulating drug bioavail-
ability (the main contributor of prehepatic clear-
ance of drugs) [11]. However, little is known
about the interspecies differences in the distribu-
tion pattern of individual isoforms and functions
at the level of mRNA expression for the intestinal
metabolizing enzymes. Therefore, the genomic
comparison of intestinal enzymes among some
species is very valuable for interspecies predic-
tion of drug bioavailability and animal scaling
for first-pass metabolism capacity. This study
provides a comparative transcriptional database
for intestinal metabolizing enzymes between
model rodent animals and human.
Materials and Methods
Materials
TRIzol reagent and superscript Choice System for
cDNA synthesis kit were purchased from Invi-
trogen (Carlsbad, CA). The BioArray high-yield
RNA transcript labeling kit was purchased from
Enzo Biochem (New York, NY). The RNeasy kit
was obtained from Qiagen (Valencia, CA). Gene-
Chips including MG 430A 2.0 for mouse, RG
U34A for rat and HG U95A for human were
purchased from Affymetrix (Santa Clara, CA).
The GeneChip hybridization and scanning for
RG U34A and HG U95A assays were performed
at the Genomic Information Support Facility at
Michigan State University (East Lansing, MI),
and those for MG 430A 2.0 were carried out at
the Seoulin Molecular Biology Technique Center
(Seoul, Korea). Human biopsy samples were
taken from the duodenum with an endoscope
as described earlier [7,16].
Animals
Male ICR mice (32–40 g) were obtained from
Orient BioCo. (Seoul, Korea) and housed in a
controlled animal room of Konkuk University,
Seoul, Korea. The mice were fed solid pellets
with water ad libitum. Male SD rats (250–300 g)
were purchased from Charles River laboratories
(Wilmington, MA) and kept at the animal facility
of the University of Michigan. The rat diets were
purchased from TestDiet Inc (Richmond, IN).
RNA isolation
The human duodenal samples were prepared
from healthy male and female volunteers (21–45
years of age, n 5 10) as described earlier [16]. All
mucosal tissues of the rat (n 5 8) and mouse
duodenum (n 5 6) were immediately scraped
with a glass slide, transferred to a new frozen
vial and dipped into liquid nitrogen. A total of
100 mg of tissue was added to 1 ml TRIzol
reagent, homogenized with a tissue razor at
maximum speed for 20 s 3 times or with a
mortar on ice. The homogenate was transferred
to a new tube and then 200 ml chloroform was
added to the TRIzol mixture. After being cen-
trifuged at 12500 rpm for 15 min at 41C, the
aqueous phase was transferred to a new tube,
and the RNA was precipitated with 500 ml of
isopropanol, and washed with 80% ethanol. The
RNA pellet was resuspended in 30–50 ml of
DNase/RNase-free water, and the concentration
was measured at 260 nm. The absorbance ratio at
wavelength 260/280 nm should be at least great-
er than 1.6. The RNA was further purified with
an RNease Mini kit (Qiagen, Valencia, CA)
according to the manufacturer’s manual. The
concentration of the purified RNA was measured
at 260 nm. The absorbance ratio at 260/280 nm of
the purified RNA should be 1.7–1.8. The purified
RNA was checked in agarose/formaldehyde gel
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for quality before further cRNA labeling. Five mg
of purified RNA was mixed with RNA loading
buffer and heated at 751C for 15 min. After
cooling down on ice for 5 min, the RNA was
loaded on 1% agarose/formaldehyde gel in 1 X
MOPS buffer. The gel was run at 80–100 V for
50 min and two sharp 18S and 28S bands should
be visible under UV.
Microarray assay
Probe synthesis from total RNA samples, hybri-
dization, detection and scanning were performed
according to the standard protocols from Affy-
metrix, Inc. (Santa Clara, CA). In the rat and
human, single stranded cDNA was transcribed
from 5–8 mg total RNA using T7-(dT)24 oligomer
primer, the primer was annealed at 701C for
10 min, and then Superscript II reverse transcrip-
tase was used for reverse transcription at 421C for
1 h. The double stranded cDNA was synthesized
from first-strand cDNA using DNA ligase, DNA
polymerase I and T4 DNA polymerase at 161C
for 2 h using SuperScript Choice System for
cDNA synthesis kit (Gibco/BRL, Grand Island,
NY, USA). The reaction was stopped by adding
10 ml of 0.5 M EDTA. The double strand cDNA
was then cleaned by phenol/chloroform
extraction with phase-locking gel and ethanol
precipitation in the presence of 1 mg of glycogen.
Biotin-labeled cRNA was synthesized from the
double strand cDNA using T7 RNA polymerase-
catalysed in vitro transcription in the presence
of biotin-labeled NTP (BioArray high yield
RNA transcription labeling kit, Enzo Biochem,
New York, NY) at 371C for 5 h, and the labeled
cRNA was purified using RNease mini kit
(Qiagen). The concentration of labeled cRNA
was measured at 260 nm. A total of 20 mg of
labeled cRNA was fragmented at 951C. Biotin-
labeled cRNA was heated at 991C for 5 min in
hybridization cocktail including hybridization
control (Bio B, C, D and Cre) and hybridized
with GeneChips (Affymetrix, Santa Clara, CA) at
421C for 16 h. The GeneChips was then washed
with non-stringent wash buffer at 501C and
stained with streptavidin phycoerythrin (SAPE)
solution. After washing at 251C, the GeneChips
was scanned with a laser scanner (Affymetrix).
In mouse, cDNA was synthesised using the
One-Cycle cDNA Synthesis Kit (Affymetrix,
Santa Clara, CA). Single stranded cDNA was
synthesised using Superscript II reverse tran-
scriptase and T7-oligo(dT) primers at 421C for
1 h. Double stranded cDNA was obtained by
using DNA ligase, DNA polymerase I and RNase
H at 161C for 2 h, followed by T4 DNA
polymerase at 161C for 5 min. After clean up
with a Sample Cleanup Module (Affymetrix,
Santa Clara, CA), ds-cDNA was used for in vitro
transcription (IVT). cDNA was transcribed using
the GeneChip IVT Labeling Kit (Affymetrix,
Santa Clara, CA), in the presence of biotin-
labelled CTP and UTP. After clean up with a
Sample Cleanup Molule (Affymetrix, Santa
Clara, CA), the biotin-labelled IVT-RNA was
fragmented. Fragmented cRNA was hybridized
to the mouse gene chip MG 430A 2.0 at 451C for
16 h according to the manufacturer’s instructions.
After hybridization, the arrays were washed in a
GeneChip Fluidics Station 450 with a non-
stringent wash buffer at 251C followed by a
stringent wash buffer at 501C. After washing, the
arrays were stained with a streptavidin–phycoer-
ythrin complex. Afterwards, they were processed
according to the procedure described above for
rat and human array. The duodenal mRNA
expression profile obtained for SLC15A1 from
microarray data analyses was validated using
semiquantitative RT-PCR. The RT-PCR assay
was performed as described previously [16].
SLC15A1 mRNA expression in the individual
biopsies determined by RT-PCR exhibited a
pattern similar to that observed with the micro-
array data (r2 5 0.89).
Data analysis
Official symbols and gene names were used in
accordance with the symbol and name lists
approved by HUGO (Human Genome Organiza-
tion) Gene Nomenclature Committee (http://
www.genenames.org). Data analysis was per-
formed using different software packages includ-
ing Microarray Suite (Affymetrix, Santa Clara, CA)
and GeneSpring 6.2 (Silicon Genetics, Redwood
City, CA). Numeric data were extracted from DAT
images and normalized using the Microarray
Suite. Gene function analysis was performed using
the gene ontology-mining tool of NetAffx, which is
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based on the Gene Ontology database (http://
www.geneontology.org). GeneSpring also uses
data found publicly in genomics databases to
build gene ontologies based on annotation infor-
mation. For the present GeneChip probe array
study, the data for each gene represent data from
11–20 probe pairs each approximately 25 bp in
length. For each probe pair, one probe is a perfect
match while the other has a single mismatch at
nucleotide 13. The mismatch probe works as an
internal control to evaluate the cross hybridiza-
tions between closely related target sequences. The
overall target-specific intensity was obtained by
the difference between the intensity of perfect
match and the mismatch probes. GeneChip
Operating Software (GCOS, Affymetrix, CA) was
used to determine the absolute analysis metrics
(Detection, Detection p-value) using the scanned
probe array data and compared between the
different treatment group signals to generate the
Change, Change p-value, and Signal log ratio (fold
change). For normalization, data from each ex-
pression array were scaled, so that the overall
fluorescence intensity across each chip was
equivalent (average target intensity set at 500).
The ‘Selected Probe Sets’ method was applied
using the normalization control probe sets. Equiv-
alency for arrays being compared was assessed
based on the scaling/normalization factors calcu-
lated by the ‘Selected Probe Sets’ (GCOS, Affyme-
trix, CA). The one-sided Wilcoxon’s signed rank
test was employed to generate the detection p-
value. If the overall intensity of perfect match was
much larger than that of mismatch, the detection p-
value would be small. The probe set would be
regarded as present if the p-value was less than
0.04 and if the p-value was higher than 0.06, the
probe set would be regarded as absent. The
detection threshold was set as the ‘present’ call
output from GCOS (po0.05). Two sets of algo-
rithms were generated and they were used to
generate change significance and change quantity
metrics for every probe set. The change algorithm
generated a Change p-value and an associated
fold-change value. The second algorithm gave a
quantitative estimate of the change in gene
expression in the form of Signal Log Ratio. The
level of gene expression was regarded as increased
if its Change p-value was less than 0.0025 and the
gene expression would be considered to be
decreased if its Change p-value was greater than
0.9975. Only relative changes equal or greater than
2-fold level of expression were considered. For a
given gene transcript in any chip-to-chip compar-
ison, GCOS generates a ‘change call’ parameter
(‘increase’ or ‘decrease’) based on a consideration
of signal specificity as well as intensity.
Results
Expression profiles of 22690 gene sequences in
mouse intestine, 8739 in rat and 12559 in human
were analysed. Detected genes were ca. 60%, 40%
and 47% from mouse, rat and human intestine,
respectively. This paper focused on the expres-
sion of metabolizing enzymes as critical factors
modulating prehepatic clearance of many oral
substrates. As shown in Table 1, the total
numbers of metabolizing enzymes detected were
95, 33 and 68 genes in mouse, rat and human
intestine, respectively. Relatively higher intensi-
ties of gene expression were observed in glucur-
onosyltransferases and acyltransferases.
Figure 1 shows the expression of P450s.
Several types of Cyp3a including Cyp3a25,
Cyp3a9 and Cyp3a4 were dominantly expressed
in mouse, rat and human. Expression intensities
Table 1. The number of genes expressed in mouse, rat and human intestine













Cytochrome P450s 30 71 16 862 24 275
Glucuronosyltransferases 5 786 7 2391 6 2144
Glutathione S-transferases 19 253 1 150 9 1145
Sulfotransferases 15 84 3 1167 15 422
Acetyltransferases 15 71 4 583 9 882
Acyltransferases 11 232 2 12950 5 1474
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of cytochrome P450s were in order of Cyp3a25
4 Cyp4v3 4 Cyp2d26 4 Cyp2b20 4 Cyp2c65 4
Cyp4f14 in mouse, Cyp3a9 4 Cyp2b19 4 Cyp4f1 4
Cyp17a1 4 Cyp2d18 4 Cyp27a1 in rat, and CYP3A4
4 CYP3A5 4 CYP4F3 4 CYP2C18 4 CYP2C9 4
CYP2D6 4 CYP3A7 4 CYP11B1 4 CYP2B6 in
human. The expressions of other P450s were
minor or negligible. Of UDP-glucuronsyltrans-
ferases (UGT), higher expression levels were
observed in Ugt1a6 (mouse), Ugt1a1 and Ugt1a7
(rat) and UGT2B15 and UGT2B17 of human
compared with the other UGTs (Figure 2). As
shown in Figure 3, expression intensity of glu-
tathione S-transferases was in the order Gstp1 4
Gstm3 4 Gsta2 4 Mgst3 4 Mgst1 4 Gsto1 4
Gstm1 4 Mgst2 in mouse, and MGST3 4 GSTP1
4 GSTA2 4 GSTM4 4 MGST2 4 GSTM1 in
human. Figure 4 shows that sulfotransferases had
a similar gene expression pattern between mouse
and rat. Sult1b1 was distinctly expressed both in
mouse and rat, but not detected in human. Human
revealed a dramatically higher intensity of ST1A3
and SULT1A2 expression. Of the acetyltransferases
(Figure 5), Acat1 and Sat1 were highly expressed
in mouse, Dlat in rat, and SAT1 and CART in
human. Figure 6 shows the acyltransferase expres-
sion levels in these species. Rat showed a very
Figure 1. Comparative gene expression for various cytochrome P450s in the intestine of mice, rats and humans (n 4 6).
Expression levels were measured by the intensity of hybridization signal using GeneChip array. (CYP1A1, cytochrome P450,
family 1, subfamily a, polypeptide 1)
Figure 2. Comparative gene expression for various glucurono-
syltransferases in the intestine of mice, rats and humans (n 4 6).
Expression levels were measured by the intensity of hybridiza-
tion signal using GeneChip array. (UGT1A1, UDP-glucuronosyl-
transferase 1a1; UGT1A4, bilirubin UDP-glucuronosyltransferase
isozyme 2; UGT1A6, UDP-glucuronosyltransferase 1 family,
polypeptide A6; UGT1A7, UDP-glucuronosyltransferase 1a7;
UGT2B2, androsterone UDP-glucuronosyltransferase; UGT2B3,
liver 17 beta-hydroxysteroid UDP-glucuronosyltransferase;
UGT2B4, UDP-glucuronosyltransferase 2b4; UGT2B5, UDP-
glucuronosyltransferase 2 family, member 5; UGT2B7, 3,4-
catechol estrogen UDP-glucuronosyltransferase; UGT2B11,
UDP-glucuronosyltransferase 2B; UGT2B15, UDP glucuronosyl-
transferase; UGT2B17, C19steroid specific UDP-glucuronosyl-
transferase; UGT8, UDP-glucuronosyltransferase 8; B3GALT4,
UDP-Gal:betaGalNAc beta 1,3-galactosyltransferase, polypeptide
4; B3GAT3, beta-1,3-glucuronyltransferase 3 (glucuronosyltrans-
ferase I); LARGE, like-glycosyltransferase; NPHP4, AKIAA0673
protein)
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high expression intensity of Dgat1, and mouse
expressed Dgat1 and Acaa2 at high levels. In
human, AGPAT2 and AGPAT1 were found at
higher levels.
Discussion
It was widely recognized that there were marked
inter- or intraspecies differences in distribution
and functions of each metabolizing enzyme class
including cytochrome P450s and transferases.
However, since these studies focused on the
hepatic metabolism [17], there has been very
poor information regarding other tissues such as
intestine. Therefore, it is necessary to develop
P450 and transferase-based differential screening
systems that may able to predict the risk and
pharmacological responses of xenobiotics be-
tween animals and humans. Recently, these
screening systems are being accomplished by
use of genomic techniques. Molecular probes are
being used to screen the levels of gene expression
of drug-related enzymes in an effort to determine
whether expression of certain P450 forms or
transferases is associated with increased drug
discovery and risk assessment [1,2].
Cytochrome P450s, a class of phase I metabo-
lizing enzymes, are dominantly expressed in
liver and intestine to regulate metabolism and
oral bioavailability, and these enzymes have
shown a very wide range of substrate specifi-
cities [18,19]. For this reason, examining the
differences in the expression levels of these
enzymes among some species may provide
insight into the differences in PK and drug
bioavailability properties. Up to now, there are
more than 71 characterized cytochrome P450
genes by HUGO. These enzymes are responsible
for the metabolism (at least partial metabolism)
of approximately 75% of all drugs, with the
CYP3A subfamily being responsible for nearly
half of this activity [20,21]. Because of their wide
substrate spectrums and potential for numerous
drug–drug interactions in both preclinical and
clinical studies, these subfamilies CYP1A,
CYP2A, CYP2B, CYP2D, CYP2E and CYP3A are
considered as key enzymes [21–23]. In our study,
mice showed primary expression of Cyp3a25,
Cyp4v3 and Cyp2d26, and rats revealed higher
Figure 3. Comparative gene expression for various glutathione S-transferases in the intestine of mice, rats and humans (n 4 6).
Expression levels were measured by the intensity of hybridization signal using GeneChip array. (GSTA2-4, glutathione S-
transferase, alpha 2-4; GSTK1, glutathione S-transferase, kappa 1; GSTM1-6, glutathione S-transferase, mu 1-6; GSTO1,
glutathione S-transferase, omega 1; GSTP1, glutathione S-transferase, pi 2; GSTT1-3, glutathione S-transferase, theta 1-3; GSTZ1,
glutathione transferase, zeta 1 (maleylacetoacetate isomerase); MGST1-3, microsomal glutathione S-transferase 1-3)
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transcription of Cyp3a9, Cyp2b19, Cyp4f1 and
Cyp17a1. On the other hand, humans have
dominantly expressed CYP3A4, CYP3A5,
CYP4F3 and CYP2C subfamilies. Expression
intensities of the other minor P450 genes were
also considerably different among these species.
Significant expression of Cyp3a25 in mouse
intestine has been also reported by earlier
investigators [24,25], though an identification
study of intestinal P450s has not been well
described in mouse intestine compared with rat
and human. It is well known that the CYP3A4 is
a predominant P450 enzyme in human intestine,
and Cyp3a9 in rat intestine [26,27]. Wacher
et al. [28] reported that CYP3A4 in human
intestine plays a significant role in the first-pass
metabolism of 50–70% of marketed drugs.
Zierold et al. [29] and Xue et al. [30] reported
that the human CYP3A4 is thought to be the
homolog of the rat Cyp3a9, though the two
enzymes are not identical because of four
different amino acids in the substrate recognition
site. Human CYP3A4 reveals higher homology of
DNA sequence with rat Cyp3a9 (81%) than that
of mouse Cyp3a25 (76%). These data might
indicate that there are extensive interspecies
variations in the preference of substrate structure
recognition, though few members of CYP3A
subfamily, including Cyp3a25, Cyp3a9 and
CYP3A4, are expressed as the principal gene in
these species. Therefore, this result may partially
explain ‘why the oral first-pass metabolism of
many substrates differs in these species’.
Probably the most common conjugation reac-
tion is the synthesis of glucuronic acid deriva-
tives (glucuronides). Aliphatic alcohols, phenols,
carboxylic acids, mercaptans, primary and
secondary aliphatic amines, and carbamates are
Figure 4. Comparative gene expression for various sulfotransferases in the intestine of mice, rats and humans (n 4 6). Expression
levels were measured by the intensity of hybridization signal using GeneChip array. (CHST1-4, carbohydrate (keratan sulfate
Gal-6) sulfotransferase 1-4; CHST7, chondroitin 6-sulfotransferase like protein; GAL3ST1, galactosylceramide sulfotransferase;
HS2ST1, heparan sulfate 2-O-sulfotransferase 1; HS3ST1, heparan sulfate (glucosamine) 3-O-sulfotransferase 1; HS6ST1, heparan
sulfate 6-O-sulfotransferase 1; NDST1-2, N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1-2; SULT1A1, minoxidil
sulfotransferase; SULT1A2, thermostable phenol sulfotransferase (STP2); SULT1B1, sulfotransferase family 1B, member 1;
SULT1C1, sulfotransferase family, cytosolic, 1C, member 1; SULT1D1, sulfotransferase family 1D, member 1; SULT2A1,
dehydroepiandrosterone sulfotransferase (STD) gene; SULT2B1, sulfotransferase family, cytosolic, 2B, member 1; SULT4A1,
sulfotransferase (Sulfokinase) like gene; SULT5A1, sulfotransferase family 5A, member 1; TPST2, protein-tyrosine sulfotransfer-
ase 2; ST1A3, aryl sulfotransferase; TPST1, tyrosylprotein sulfotransferase-1; TPST2, tyrosylprotein sulfotransferase; UST,
dermatan/chondroitin sulfate 2-sulfotransferase)
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converted to their beta-glucuronide derivatives
by UDP-glucuronosyltransferase (UGT). In our
study, higher expression levels were observed in
Ugt1a6 of mouse, Ugt1a1 and Ugt1a7 of rat, and
UGT2B15 and UGT2B17 of human when com-
pared with other glucuronosyltransferases. Glu-
tathione S-transferases are ubiquitous
multifunctional proteins involved in the de-
toxification of endogenous and xenobiotic com-
pounds using either glutathione conjugation or
glutathione peroxidase activity [31,32]. The major
roles of GSTs are the metabolism of electrophilic
carcinogens and alkene and arene oxides [33].
The data show interspecies variability for the
expression pattern of glutathione S-transferases.
Expression intensity was high in Sgtp1, Gstm3,
Gsta2, Mgst3, Mgst1 and Gsto1 in mouse, and
MGST3, GSTP1, GSTA2, GSTM4 and MGST2 in
human. However, in rats, the enzyme Gstm5
was merely observed at the lower level. Sulfo-
transferase (SULT) catalyses the transfer of a
sulfate group to the hydroxyl group of drug
compounds [34]. Sult1b1 was distinctly ex-
pressed in both mouse and rat, but not detected
in humans. On the other hand, human revealed a
dramatically higher intensity of ST1A3 and
SULT1A2 expression. It can be summarized that
sulfotransferases have a similar gene expression
pattern between mouse and rat, but not human.
Acetylation of drug compounds is catalysed in
human and animals by various types of acetyl-
transferases such as MYST histone acetyltrans-
ferases (MYSTs), N-acetyltransferases (NATs)
and spermidine/spermine N1-acetyltransferases
(SATs). The data have shown a variety of gene
expression profiles for acetyltransferases de-
pending on the species. Acat1 and Sat1 were
highly expressed in mouse, Dlat in rat, and SAT1
and CART in human in which SAT1 expression
level was 3–4 fold higher than CART. Several
types of xenobiotic carboxylic acids including
aromatic, heteroaromatic, arylacetic, cinnamic
and aryloxyacetic are conjugated with a variety
of endogenous amino acids including glycine,
Figure 5. Comparative gene expression for various acetyltransferases in the intestine of mice, rats and humans (n46). Expression
levels were measured by the intensity of hybridization signal using GeneChip array. (ACAT1, acetyl-coenzyme
A acetyltransferase 1; ACAT3, acetyl-coenzyme A acetyltransferase 3; ARD1, N-acetyltransferase ARD1 homolog (S. cerevisiae);
BAAT, bile acid-coenzyme A: amino acid N-acyltransferase; CRAT, carnitine acetyltransferase; DLAT, dihydrolipoamide S-
acetyltransferase; GCAT, glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase); GNPNAT1, glucosamine-
phosphate N-acetyltransferase 1; MYST2-4, MYST histone acetyltransferase 2-4; NAT1, arylamine N-acetyltransferase; NAT2,
N-acetyltransferase 2 (arylamine N-acetyltransferase); NAT5, N-acetyltransferase 5 (ARD1 homolog, S. cerevisiae); NAT6, N-
acetyltransferase 6; SAT1, spermidine/spermine N1-acetyl transferase 1; MFGE8, O-acetyltransferase; AANAT, serotonin N-
acetyltransferase gene; GCN5L2, histone acetyltransferase; HAT1, histone acetyltransferase 1)
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glutamine and taurine, prior to excretion in
mammals [35]. It was observed that the acyl-
transferase expression levels are extensively
different in mouse, rat and human. Rat showed
a very high expression intensity of Dgat, and
mouse expressed Dgat1 and Acaa2 at high levels.
However, in human, AGPAT2 and AGPAT1 were
found as the primary enzyme genes compared
with other acyltransferases.
The potential role of intestinal enzymes on
drug first-pass metabolism has become increas-
ingly recognized. Although animal models do
not provide direct information that can be
extrapolated to humans, drug metabolism stu-
dies will all benefit from the selection of animal
models species that closely approximates human
metabolism. Since it is very difficult technically
to assay the expression of whole enzymes at
proteomic levels, it is readily accepted that the
gene expression studies using microarray tech-
nology is an essential tool for predicting func-
tional expression of intestinal proteins. It is still
arguable that the transcriptional profile may not
be consistent with functional protein levels.
Nevertheless, several recent investigations have
revealed positive correlation between mRNA
expression and regulation of functional proteins
[7,36–40]. Berggren et al. [39] reported that
mRNA level of CYP3A4 was significantly corre-
lated with its protein levels in small intestine.
Overall, the data reveal that rodent animals and
humans have a variety of different transcrip-
tional profiles for metabolizing enzymes in the
small intestine. To our knowledge, there has been
no report directly describing interspecies differ-
ence in intestinal expression of metabolism
enzymes at genomic levels. Therefore, this
transcriptional data can lead to more effective
use of animal models in oral drug development
and application to human.
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